Moreover, SPP1 has been demonstrated to be significantly overexpressed in afatinib-resistant lung cancer cells, and that the knockdown of SPP1 increases the chemotherapy sensitivity of lung cancer cells. This evidence concerns the gene SPP1 and lung carcinoma.